In last trading session, Seres Therapeutics Inc (NASDAQ:MCRB) saw 0.81 million shares changing hands with its beta currently measuring 2.55. Company’s recent per share price level of $0.69 trading at $0.05 or 8.05% at ring of the bell on the day assigns it a market valuation of $120.10M. That closing price of MCRB’s stock is at a discount of -121.74% from its 52-week high price of $1.53 and is indicating a premium of 21.74% from its 52-week low price of $0.54. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.91 million shares which gives us an average trading volume of 1.50 million if we extend that period to 3-months.
For Seres Therapeutics Inc (MCRB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.67. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.08 in the current quarter.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Upright in the green during last session for gaining 8.05%, in the last five days MCRB remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $0.69 price level, adding 11.61% to its value on the day. Seres Therapeutics Inc’s shares saw a change of -16.99% in year-to-date performance and have moved -9.89% in past 5-day. Seres Therapeutics Inc (NASDAQ:MCRB) showed a performance of -15.66% in past 30-days. Number of shares sold short was 17.23 million shares which calculate 22.25 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1.25 to the stock, which implies a rise of 44.8% to its current value. Analysts have been projecting 1.25 as a low price target for the stock while placing it at a high target of 1.25. It follows that stock’s current price would drop -81.16% in reaching the projected high whereas dropping to the targeted low would mean a loss of -81.16% for stock’s current value.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 20M for the same. And 5 analysts are in estimates of company making revenue of 5M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.34% during past 5 years.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Insiders are in possession of 13.19% of company’s total shares while institution are holding 36.95 percent of that, with stock having share float percentage of 42.57%. Investors also watch the number of corporate investors in a company very closely, which is 36.95% institutions for Seres Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at MCRB for having 22.72 million shares of worth $16.44 million. And as of 2024-06-30, it was holding 15.5489 of the company’s outstanding shares.
The second largest institutional holder is FLAGSHIP PIONEERING INC., which was holding about 23.12 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.2573 of outstanding shares, having a total worth of $16.73 million.
On the other hand, Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 6.81 shares of worth $4.7 million or 3.91% of the total outstanding shares. The later fund manager was in possession of 3.86 shares on Dec 31, 2024 , making its stake of worth around $2.66 million in the company or a holder of 2.21% of company’s stock.
